ICICI Pru Pharma Healthcare & Diagnostics (P.H.D) Fund
Ticker: mf12623
Decent
48/100
☆ Add to Watchlist
More Options
S
SBI MNC Fund
The SBI MNC Fund shows a decent potential for growth with a solid investment strategy focused on multinational companies. However, some risks related to governance and execution should be monitored.
View details
I
Invesco India Money Market Fund
The fund shows moderate potential but faces challenges in growth and profitability consistency.
View details
I
ICICI Pru Credit Risk Fund
The ICICI Pru Credit Risk Fund shows potential for moderate returns, but investors should be cautious of market volatility and execution risks.
View details
D
DSP Arbitrage Fund
The DSP Arbitrage Fund shows decent potential but faces challenges in profitability and growth drivers.
View details
I
ICICI Pru Thematic Advantage Fund
The ICICI Pru Thematic Advantage Fund shows decent potential with a balanced approach to growth and profitability, but investors should remain cautious of execution risks.
View details
A
Aditya Birla SL Midcap Fund
The fund has a decent outlook with some growth potential, but risks remain in execution and profitability.
View details
J
JM Flexicap Fund
JM Flexicap Fund shows a decent potential for growth with manageable risks, making it a reasonable investment option.
View details
U
UTI Multi Asset Allocation Fund
The UTI Multi Asset Allocation Fund shows decent potential but faces challenges in profitability and valuation metrics. Investors should be cautious and monitor performance closely.
View details
H
HDFC Banking and PSU Debt Fund
The fund shows potential but carries significant risks due to inconsistent performance and market conditions.
View details
A
Aditya Birla SL Value Fund
The fund shows potential for moderate growth but carries some risks that need to be monitored.
View details
K
Kotak Income Plus Arbitrage Omni FOF
The fund presents several risks with limited growth potential and weak technicals, making it a risky investment.
View details
D
DSP Low Duration Fund
The DSP Low Duration Fund shows decent potential with stable growth and manageable risks, but investors should be cautious of execution challenges.
View details
K
Kotak Banking and PSU Debt Fund
The fund shows potential for moderate returns, but investors should be cautious due to competitive pressures and execution risks.
View details
U
Union Liquid Fund
Union Liquid Fund shows decent performance with stable fundamentals but lacks strong growth catalysts.
View details
U
UTI Corporate Bond Fund
UTI Corporate Bond Fund shows decent potential but faces several risks that could impact future performance.
View details
I
ICICI Pru Dividend Yield Equity Fund
The fund shows decent potential but faces challenges in profitability and execution risks.
View details
Business Overview
The ICICI Pru Pharma Healthcare & Diagnostics (P.H.D) Fund is designed for investors seeking exposure to the booming healthcare and pharmaceutical sectors. This fund focuses on companies that are pivotal in delivering healthcare solutions, making it ideal for those looking to capitalize on the growth potential of the industry. With a strong management team and a strategic investment approach, this fund aims to provide long-term capital appreciation.
- Focuses on healthcare and pharmaceutical sectors
- Ideal for growth-oriented investors
- Managed by experienced professionals
- Diversified portfolio for risk mitigation
- Potential for long-term capital appreciation
Investment Thesis
ICICI Pru Pharma Healthcare & Diagnostics Fund presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital healthcare services, and attractive valuation compared to peers. These factors position the fund favorably in a rapidly evolving market.
- Backed by the reputable ICICI Group, ensuring trust and stability.
- Expanding digital services align with industry trends and consumer preferences.
- Valuation metrics indicate a favorable entry point compared to industry peers.
- Focus on healthcare and diagnostics positions the fund in a resilient sector.
- Strong growth potential driven by increasing healthcare demand and innovation.
Opportunity vs Risk
Opportunities
- Growing healthcare sector in India
- Increased demand for diagnostics services
- Strong government healthcare initiatives
- Potential for high returns
- Diversification in investment portfolio
Risks ⚠️
- Regulatory changes in healthcare
- Market volatility affecting returns
- Competition from other funds
- Economic downturn impacts
- Management performance variability
Peer Perspective
ICICI Pru P.H.D Fund trades at a slight premium compared to peers like HDFC Healthcare Fund and SBI Pharma Fund. A sustained growth acceleration and improved margin stability could trigger a positive rerating.
📊 Stock Investment Checklist (100 Points)
ICICI Pru Pharma Healthcare & Diagnostics (P.H.D) Fund • Updated: 2025-09-29 14:49:14
-
10BusinessHighThe sector is future-ready with a clear model, but faces competition.
-
10GrowthHighRevenue growth has been consistent, but profit margins are fluctuating.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is inconsistent compared to net profit.
-
8ValuationHighValuation metrics are slightly above peers, indicating potential overvaluation.
-
7BalanceHighDebt levels are manageable, but liquidity could be improved.
-
5GovernanceGoodPromoter holding is stable, but there are some concerns about disclosures.
-
3DriversLowGrowth drivers are present, but execution risks are significant.
-
0TechnicalsLowMarket sentiment is weak with low liquidity and negative price action.
Final Score & Verdict
Score 48 / 100
• Decent
The fund shows potential in a growing sector but faces challenges in profitability and market sentiment.